We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

107 hedge funds and large institutions have $849M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,957% more call options, than puts

Call options by funds: $642K | Put options by funds: $21K

119% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

1% less funds holding

Funds holding: 108 → 107 (-1)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

32% less capital invested

Capital invested by funds: $1.25B → $849M (-$401M)

Holders
107
Holders Change
-1
Holders Change %
-0.93%
% of All Funds
1.86%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
18
Increased
46
Reduced
21
Closed
19
Calls
$642K
Puts
$21K
Net Calls
+$621K
Net Calls Change
-$353K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$22.4M
2
BC
Boxer Capital
California
+$11.7M
3
JP Morgan Chase
JP Morgan Chase
New York
+$10.2M
4
CS
Candriam SCA
Luxembourg
+$8.01M
5
Citadel Advisors
Citadel Advisors
Florida
+$7.67M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$20M
3
FCM
Farallon Capital Management
California
-$10.9M
4
BlackRock
BlackRock
New York
-$10.9M
5
RSCM
Rock Springs Capital Management
Maryland
-$10.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
OCA
26
Octagon Capital Advisors
New York
$3.94M – – –
Lord, Abbett & Co
27
Lord, Abbett & Co
New Jersey
$3.73M +$4.43M +189,101 New
Charles Schwab
28
Charles Schwab
California
$3.59M +$425K +18,137 +11%
Morgan Stanley
29
Morgan Stanley
New York
$3.29M -$1.77M -75,795 -31%
Deutsche Bank
30
Deutsche Bank
Germany
$3.01M -$2.62M -111,848 -42%
EC
31
EcoR1 Capital
California
$2.83M – – –
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$2.52M -$414K -17,707 -12%
N
33
Nuveen
North Carolina
$2.45M -$1.14M -48,513 -28%
SAM
34
Silvercrest Asset Management
New York
$2.29M +$1.45M +61,920 +114%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2M +$506K +21,635 +27%
Citigroup
36
Citigroup
New York
$1.98M +$2.25M +95,997 +2,222%
HF
37
HRT Financial
New York
$1.92M +$2.28M +97,313 New
ACH
38
ArrowMark Colorado Holdings
Colorado
$1.64M – – –
Swiss National Bank
39
Swiss National Bank
Switzerland
$1.33M +$1.58M +67,600 New
EGM
40
Engineers Gate Manager
New York
$1.17M +$836K +35,727 +152%
Goldman Sachs
41
Goldman Sachs
New York
$1.14M +$151K +6,442 +13%
DekaBank Deutsche Girozentrale
42
DekaBank Deutsche Girozentrale
Germany
$933K – – –
Verition Fund Management
43
Verition Fund Management
Connecticut
$902K -$1.66M -70,987 -61%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$890K +$818K +34,950 +343%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$857K +$109K +4,651 +12%
Wells Fargo
46
Wells Fargo
California
$854K +$644K +27,531 +174%
SO
47
STRS Ohio
Ohio
$820K +$442K +18,900 +83%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$805K +$289K +12,338 +43%
SG Americas Securities
49
SG Americas Securities
New York
$730K +$765K +32,677 +757%
AllianceBernstein
50
AllianceBernstein
Tennessee
$716K +$272K +11,600 +47%
1
2
3 4 5

NGM Hedge Fund Activity: Q2 2021 in Review

107 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2021, worth a combined $849M — down 32% from $1.25B a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of NGM and 18 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 46 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $22.4M. The largest seller was Point72 Asset Management, cutting an estimated $30.7M.

  • 107 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2021, down from 108 in Q1 2021.
  • Funds reported $849M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2021, down 32% quarter-over-quarter.
  • 18 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of -1 holder.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2021 was BVF Inc, an estimated $22.4M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2021 was Point72 Asset Management, an estimated $30.7M sold.

Based on aggregated 13F filings for Q2 2021.